Inhibitors of DNA methylation: beyond myelodysplastic syndromes (Q36338036)

13 August 2017

1 reference

title

Inhibitors of DNA methylation: beyond myelodysplastic syndromes (English)

1 reference

13 August 2017

0 references

1

Pierre Fenaux

1 reference

13 August 2017

publication date

1 December 2005

1 reference

Nature Clinical Practice Oncology

13 August 2017

published in

1 reference

13 August 2017

volume

2 Suppl 1

1 reference

13 August 2017

page(s)

S36-44

1 reference

5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

Cancer epigenetics comes of age

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

Clinical resistance to imatinib: mechanisms and implications

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

Initial therapy for chronic myelogenous leukemia: playing the odds

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

DNA hypermethylation in tumorigenesis: epigenetics joins genetics

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

DNA methylation, methyltransferases, and cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPONC0351

1 reference

7 January 2021

Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

5' CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia: A southwest oncology group study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

5-Azacytidine in Refractory Acute Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

Combined etoposide and 5-azacitidine in children and adolescents with refractory or relapsed acute nonlymphocytic leukemia: a Pediatric Oncology Group Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia intergroup study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: a Pediatric Oncology Group randomized phase II study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

Pilot study of 5-azacytidine (5-AZA) and carboplatin (CBDCA) in patients with relapsed/refractory leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

The World Health Organization (WHO) classification of the myeloid neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

Epigenetic targets in hematopoietic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

DNA hypomethylation leads to elevated mutation rates

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

Effects of 5-aza-2'-deoxycytidine on matrix metalloproteinase expression and pancreatic cancer cell invasiveness

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

Chromosomal Instability and Tumors Promoted by DNA Hypomethylation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0351

7 January 2021

Identifiers

DOI

10.1038/NCPONC0351

1 reference

Dimensions Publication ID

13 August 2017

1036017765

0 references

1 reference